Drug intelligence / Profile preview

ALN1003

Development stage: Preclinical
Lead developer: Alaunos Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ALN1003 is an investigational, non-hormonal small molecule being developed by Alaunos Therapeutics for the treatment of obesity. Currently in the preclinical stage of development, the drug is designed for oral administration. While the specific biological target and mechanism of action remain undisclosed, the program represents a strategic expansion for Alaunos into the metabolic disease space, utilizing a non-hormonal approach to weight management that is distinct from the prevailing GLP-1 receptor agonist class.

Beyond the preview

Go deeper on ALN1003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALN1003.

Explore the full profile